Long‐term (5‐year) clinical evaluation of the Resolute zotarolimus‐eluting coronary stent: The RESOLUTE US clinical trial

• Published in: Catheterization and cardiovascular interventions 2020-05, Vol.95 (6), p.1067-1073
• Main Authors: Kirtane, Ajay J., Yeung, Alan C., Ball, Michael, Carr, Jeffrey, O'Shaughnessy, Charles, Mauri, Laura, Liu, Minglei, Leon, Martin B.
• Format: Article
• Language: English
• Subjects: Aged; Antiplatelet therapy; Cardiovascular Agents - administration & dosage; Cardiovascular Agents - adverse effects; Coronary artery; Coronary Artery Disease - diagnostic imaging; Coronary Artery Disease - mortality; Coronary Artery Disease - therapy; Coronary Thrombosis - etiology; Coronary Thrombosis - prevention & control; Diabetes; Diabetes mellitus; Drug-Eluting Stents; drug‐eluting stent; Dual Anti-Platelet Therapy; Female; Heart attacks; Heart surgery; Humans; Implants; Lesions; Male; Middle Aged; Myocardial infarction; Percutaneous Coronary Intervention - adverse effects; Percutaneous Coronary Intervention - instrumentation; Percutaneous Coronary Intervention - mortality; percutaneous coronary interventions; Prospective Studies; Recurrence; Resolute US; Resolute zotarolimus‐eluting stent; Risk Assessment; Risk Factors; Safety; Sirolimus - administration & dosage; Sirolimus - adverse effects; Sirolimus - analogs & derivatives; Stents; Thrombosis; Time Factors; Treatment Outcome; United States
• ISSN: 1522-1946; 1522-726X
• DOI: 10.1002/ccd.28392

Objectives To assess the long‐term safety and efficacy of the Resolute zotarolimus‐eluting stent (R‐ZES). Background The R‐ZES has been associated with low rates of adverse events over short‐intermediate term follow‐up. However, reliable assessment of the safety and efficacy of any implanted device requires long‐term evaluation. Methods The RESOLUTE US trial was a prospective, observational study conducted at 116 U.S. sites and enrolled patients with de novo coronary lesions. Patients were followed clinically for 5 years with independent event adjudication and data monitoring. Results A total of 1,402 patients (1,573 lesions) were enrolled; 34% had diabetes mellitus and 75% had ACC type B2/C lesions. The 5‐year rate of target lesion failure (TLF) was 12.3%, target lesion revascularization was 6.5%, target vessel myocardial infarction was 3.2%, and cardiac death was 4.1%. Dual antiplatelet therapy usage was 94% at 1 year and 47% at 5 years, with a 0.1% and 0.5% respective incidence of definite or probable stent thrombosis. The 5‐year rate of TLF was 16.9% among patients with diabetes mellitus and 14.7% in patients with at least one small (≤2.5 mm) vessel treated. Covariates independently associated with 5‐year TLF in multivariable analysis included diabetes mellitus (odds ratio [OR] 1.89, p